Evidence map›Paper›PMID 32381037›Full record

ArticleTrials2020

Correction to: Update on the EFFECTS study of fluoxetine for stroke recovery: a randomised controlled trial in Sweden.

Erik Lundström, Eva Isaksson, Per Näsman, Per Wester, Björn Mårtensson, Bo Norrving, Håkan Wallén, Jörgen Borg, Martin Dennis, Gillian Mead and 4 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Trials, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery.The Cochrane database of systematic reviews · 2021
    Pooled it
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Erik LundströmDepartment of Neuroscience, Neurology, Uppsala University, Akademiska, Sjukhuset, SE-751 85, Uppsala, Sweden. erik.lundstrom@neuro.uu.se.
Eva IsakssonDepartment of Clinical Neuroscience, Neurology, Karolinska Institutet, Nobels väg 6, SE-171 76, Stockholm, Sweden.
Per NäsmanCentre for Safety Research, KTH Royal Institute of Technology, TR10 B, SE-100 44, Stockholm, Sweden.
Per WesterDepartment of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, SE-182 88, Stockholm, Sweden.
Björn MårtenssonDepartment of Clinical Neuroscience, Karolinska Institutet, SE-171 77, Stockholm, Sweden.
Bo NorrvingDepartment of Clinical Sciences, Lund, Neurology, Skåne University Hospital, Lund University, SE-221 85, Lund, Sweden.
Håkan WallénDepartment of Clinical Sciences, Division of Cardiovascular Medicine, Danderyd Hospital, Karolinska Institutet, SE-182 88, Stockholm, Sweden.
Jörgen BorgDepartment of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, SE-182 88, Stockholm, Sweden.
Martin DennisRoyal Infirmary, University of Edinburgh, Edinburgh, EH16 4SB, UK.
Gillian MeadRoyal Infirmary, University of Edinburgh, Edinburgh, EH16 4SB, UK.
Graeme J HankeyMedical School, The University of Western Australia, Perth, Australia.
Maree L HackettThe George Institute for Global Health, Faculty of Medicine, University of New South Wales Sydney, Sydney, Australia.
Katharina S SunnerhagenInstitute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
EFFECTS Trial Collaboration

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Following publication of the original article [1], we were notified that one of the corresponding author's affiliations was omitted.

Identifiers

PMID32381037
PMCPMC7203841

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.